Martin v. Medtronic, Inc.
32 F. Supp. 3d 1026
D. Ariz.2014Background
- Plaintiffs Debra and Patrick Martin sued Medtronic and Medtronic Sofamor Danek alleging injuries from use of Infuse® Bone Graft (rhBMP-2/ACS/LT‑Cage) in an off‑label posterolateral spine procedure.
- Infuse is a Class III device that received FDA Premarket Approval (PMA) for a specific ALIF (anterior lumbar interbody fusion) single‑level use; plaintiffs allege the manufacturer promoted other (unapproved) uses.
- Plaintiffs allege widespread off‑label promotion (sales reps in ORs, paid “opinion leaders,” literature manipulation, gifts) and that Medtronic knew off‑label uses caused serious harms (ectopic bone, radiculitis, cysts, implant displacement).
- Debra alleges state law claims: fraudulent misrepresentation, strict liability (failure to warn, design defect, misrepresentation), negligence, breach of express warranty, and violation of Arizona consumer protection laws; Patrick asserts loss of consortium.
- Defendants moved to dismiss under Rules 9(b) and 12(b)(6) principally arguing express and implied preemption by the Medical Device Amendments (MDA/21 U.S.C. §360k) and insufficiently pleaded fraud particulars.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether state claims are expressly preempted by §360k because Infuse obtained PMA | Martin: PMA covered only the combined device/use approved; off‑label promotion and unapproved uses of the bone protein fall outside federal review so state claims can proceed | Medtronic: PMA imposes federal requirements on the device generally; off‑label promotion and related state claims are preempted or conflict with federal scheme | Court: Rejected Ramirez approach; preemption analysis applies to off‑label promotion claims — some claims may be preempted; analysis done claim‑by‑claim |
| Whether off‑label promotion claims are impliedly preempted under Buckman (i.e., are they really FDCA enforcement attempts) | Martin: Fraud, warranty and consumer claims are traditional state causes and allege false/misleading off‑label promotion, not mere enforcement of FDCA | Medtronic: Claims rest on FDCA duties created by federal law (no independent state duty) and thus are impliedly preempted | Court: Fraud‑based claims tied to off‑label promotion can avoid implied preemption if grounded in traditional state law; general implied‑preemption argument fails for fraud allegations rooted in common law |
| Whether fraud and consumer claims pleaded with Rule 9(b) particularity | Martin: Alleged numerous specific misrepresentations and promotional schemes | Medtronic: Pleading is generalized; lacks particular misrepresentations relied upon by plaintiff/physician | Court: Dismissed fraud and consumer fraud claims for failure to plead reliance/specific misrepresentations with particularity; granted leave to amend as to off‑label promotion‑based fraud claims |
| Preemption status of non‑fraud claims (failure‑to‑warn, design defect, negligence, warranty) | Martin: Some theories (failure to report adverse events to FDA; warranty or negligence tied to off‑label harms) can be parallel to federal duties and survive | Medtronic: These claims either impose additional labeling/design requirements (expressly preempted) or depend on federal prohibitions against off‑label promotion (impliedly preempted) | Court: Design defect and labeling/warning claims tied to label/ design changes are expressly preempted; negligence and failure‑to‑warn claims based on off‑label promotion are impliedly preempted; claims based on failure to report adverse events to FDA (Stengel‑type) could survive but were dismissed for lack of causal nexus — plaintiff given leave to amend limited claims; express warranty dismissed for lack of facts but possibly salvageable on amendment |
Key Cases Cited
- Riegel v. Medtronic, Inc., 552 U.S. 312 (PMA process creates federal requirements that can preempt conflicting state law)
- Buckman Co. v. Plaintiffs’ Legal Comm., 531 U.S. 341 (state claims that effectively enforce FDCA provisions are impliedly preempted)
- Stengel v. Medtronic Inc., 704 F.3d 1224 (state failure‑to‑warn claim alleging failure to report adverse events to FDA can parallel federal duties and avoid preemption)
- United States v. Caronia, 703 F.3d 149 (truthful off‑label promotion of FDA‑approved drugs implicates First Amendment; court limited to persuasive scope)
- Perez v. Nidek Co., 711 F.3d 1109 (MDA preemption analysis applies to device requirements and off‑label contexts)
- Medtronic, Inc. v. Lohr, 518 U.S. 470 (discusses FDA review rigor and limits on state law in device context)